# Harmony Biosciences Reports Record Q2 WAKIX Revenue of ~$261M and Announces CFO Departure

> news · REPORTED · 2026-07-16

Harmony Biosciences pre-announced record preliminary Q2 2026 net revenue for WAKIX (pitolisant) of approximately $261 million, representing 30% year-over-year growth, and reaffirmed full-year 2026 revenue guidance of $1.0 billion to $1.04 billion. Simultaneously, the company disclosed that CFO Glenn Reicin stepped down effective July 16, 2026, with SVP and Controller Stephen Mollichella appointed as Interim Principal Financial Officer while a permanent search is conducted.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company focused on central nervous system disorders, with WAKIX (pitolisant) as its flagship approved product for excessive daytime sleepiness in narcolepsy patients.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.biospace.com/press-releases/harmony-biosciences-preannounces-record-quarterly-revenue-for-q2-2026-reaffirms-full-year-2026-revenue-guidance-and-announces-cfo-transition

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.